Skip to content
  • Home
  • Journalists
    • Headlines
  • Community
    • Businesses
    • Jobs
    • Learning
    • Marketplace
  • Store
(@)

Why Patients Are Being Forced to Switch to a 2nd-Choice Obesity Drug

CVS Caremark decided to stop offering Zepbound in favor of Wegovy for weight loss. It’s the latest example of limits imposed by insurance that disrupt treatments for patients.

Rebecca Robbins
Author: Rebecca Robbins

Written by

Rebecca Robbins

in

Clinical Trials, CVS Caremark Corporation, Drugs (Pharmaceuticals), Eli Lilly and Company, GLP-1 RAs (Drug), Health Insurance and Managed Care, Novo Nordisk A/S, Obesity, Prices (Fares, Fees and Rates), Research
←Transportation Secretary Gets Pressed Over Repeated Airport Failures And Musk’s FAA Cuts
Johnny Rodriguez, Country Music Star, Dead at 73→

More posts

  • Protesters, leaders push back against DHS over Newark detention facility conditions

  • Goldman and Lander spar hard over Israel

  • Snowflake climbs after Q1 results top expectations, guidance gets a boost

  • Synopsys drops despite better than expected Q2 results, big boost to full-year guidance

About Us


Support Us

Trademark & Copyright 1998 – 2025 · MOSAEC

  • Facebook
  • Instagram
  • LinkedIn
  • YouTube